A Phase 1 interventional study of Estradiol/Norethindrone acetate and Activella® in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in Canada. Open to female participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-12-08.
Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets under fed conditions.
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA Bioequivalence Statistical Methods
Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg
Drug: Estradiol/Norethindrone acetate
Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets
Drug: Activella®
Drug pages: Estradiol · Norethindrone Acetate
1 mg/0.5 mg Tablets
Also known as: Mimvey®
1 mg/0.5 mg Tablets
Also known as: Estradiol/Norethindrone acetate (generic name)
Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma)
Bioequivalence based on Norethindrone Cmax.
Time frame: Blood samples collected over a 36 hour period.
AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Bioequivalence based on Norethindrone AUC0-t.
Time frame: Blood samples collected over a 36 hour period.
AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Bioequivalence based on Norethindrone AUC0-inf.
Time frame: Blood samples collected over a 36 hour period.
Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Bioequivalence based on Corrected Total Estrone Cmax.
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Bioequivalence based on Corrected Total Estrone AUC0-t.
Time frame: Blood samples collected over a 72 hour period.
AUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Bioequivalence based on Corrected Total Estrone AUC0-inf.
Time frame: Blood samples collected over a 72 hour period.
Cmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Informational comparison of Cmax values for Uncorrected Total Estrone.
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Informational comparison of AUC0-t values for Uncorrected Total Estrone.
Time frame: Blood samples collected over a 72 hour period.
AUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Informational comparison of AUC0-inf values for Uncorrected Total Estrone.
Time frame: Blood samples collected over a 72 hour period.
Cmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
Informational comparison of Cmax values for Uncorrected Unconjugated Estradiol.
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Informational comparison of AUC0-t values for Uncorrected Unconjugated Estradiol.
Time frame: Blood samples collected over a 72 hour period.
AUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estradiol.
Time frame: Blood samples collected over a 72 hour period.
Cmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Informational comparison of Cmax values for Uncorrected Unconjugated Estrone.
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Informational comparison of AUC0-t values for Uncorrected Unconjugated Estrone.
Time frame: Blood samples collected over a 72 hour period.
AUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estrone.
Time frame: Blood samples collected over a 72 hour period.
Cmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma)
Informational comparison of Cmax values for Corrected Unconjugated Estradiol.
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Informational comparison of AUC0-t values for Corrected Unconjugated Estradiol.
Time frame: Blood samples collected over a 72 hour period.
AUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity)
Informational comparison of AUC0-inf values for Corrected Unconjugated Estradiol.
Time frame: Blood samples collected over a 72 hour period.
Cmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma)
Informational comparison of Cmax values for Corrected Unconjugated Estrone.
Time frame: Blood samples collected over a 72 hour period.
AUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Informational comparison of AUC0-t values for Corrected Unconjugated Estrone.
Time frame: Blood samples collected over a 72 hour period.
AUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity)
Informational comparison of AUC0-inf values for Corrected Unconjugated Estrone.
Time frame: Blood samples collected over a 72 hour period.
| Milestone | Estradiol/Norethindrone Acetate (Test) First | Activella® (Reference) First |
|---|---|---|
| Started | 20 | 20 |
| Completed | 19 | 20 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Milestone | Estradiol/Norethindrone Acetate (Test) First | Activella® (Reference) First |
|---|---|---|
| Started | 19 | 20 |
| Completed | 19 | 20 |
| Not completed | 0 | 0 |
| Milestone | Estradiol/Norethindrone Acetate (Test) First | Activella® (Reference) First |
|---|---|---|
| Started | 19 | 20 |
| Completed | 19 | 20 |
| Not completed | 0 | 0 |
Bioequivalence based on Norethindrone Cmax.
| ng/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| Cmax of Norethindrone (Maximum Observed Concentration of Drug Substance in Plasma) | 6.54 ± 3.62 | 6.06 ± 2.95 |
Bioequivalence based on Norethindrone AUC0-t.
| ng*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-t of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | 45.03 ± 21.76 | 46.13 ± 21.62 |
Bioequivalence based on Norethindrone AUC0-inf.
| ng*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-inf of Norethindrone(Area Under the Concentration-time Curve From Time Zero to Infinity) | 49.55 ± 23.08 | 50.68 ± 22.78 |
Bioequivalence based on Corrected Total Estrone Cmax.
| pg/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| Cmax of Corrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma) | 27076.08 ± 11600.13 | 27240.03 ± 11610.70 |
Bioequivalence based on Corrected Total Estrone AUC0-t.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-t of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | 384547.68 ± 185543.06 | 407028.98 ± 191192.18 |
Bioequivalence based on Corrected Total Estrone AUC0-inf.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-inf of Corrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity) | 380131.12 ± 163543.17 | 424801.99 ± 216597.41 |
Informational comparison of Cmax values for Uncorrected Total Estrone.
| pg/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| Cmax of Uncorrected Total Estrone(Maximum Observed Concentration of Drug Substance in Plasma) | 27256.41 ± 11652.78 | 27430.77 ± 11674.97 |
Informational comparison of AUC0-t values for Uncorrected Total Estrone.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-t of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | 397537.88 ± 193337.67 | 420763.02 ± 198975.61 |
Informational comparison of AUC0-inf values for Uncorrected Total Estrone.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-inf of Uncorrected Total Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity) | 398139.63 ± 173723.79 | 425739.45 ± 198546.75 |
Informational comparison of Cmax values for Uncorrected Unconjugated Estradiol.
| pg/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| Cmax of Uncorrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma) | 59.24 ± 19.10 | 60.33 ± 19.04 |
Informational comparison of AUC0-t values for Uncorrected Unconjugated Estradiol.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-t of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | 2016.26 ± 596.40 | 2086.39 ± 746.24 |
Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estradiol.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-inf of Uncorrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity) | 2301.59 ± 642.09 | 2274.04 ± 784.48 |
Informational comparison of Cmax values for Uncorrected Unconjugated Estrone.
| pg/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| Cmax of Uncorrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma) | 513.56 ± 165.85 | 529.23 ± 217.12 |
Informational comparison of AUC0-t values for Uncorrected Unconjugated Estrone.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-t of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | 12444.22 ± 4018.39 | 12977.00 ± 5291.36 |
Informational comparison of AUC0-inf values for Uncorrected Unconjugated Estrone.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-inf of Uncorrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity) | 13592.44 ± 3686.14 | 14155.46 ± 5300.06 |
Informational comparison of Cmax values for Corrected Unconjugated Estradiol.
| pg/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| Cmax of Corrected Unconjugated Estradiol(Maximum Observed Concentration of Drug Substance in Plasma) | 55.18 ± 19.31 | 56.24 ± 19.26 |
Informational comparison of AUC0-t values for Corrected Unconjugated Estradiol.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-t of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | 1723.44 ± 540.76 | 1793.04 ± 689.12 |
Informational comparison of AUC0-inf values for Corrected Unconjugated Estradiol.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-inf of Corrected Unconjugated Estradiol(Area Under the Concentration-time Curve From Time Zero to Infinity) | 1823.43 ± 551.11 | 1871.56 ± 730.51 |
Informational comparison of Cmax values for Corrected Unconjugated Estrone.
| pg/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| Cmax of Corrected Unconjugated Estrone(Maximum Observed Concentration of Drug Substance in Plasma) | 492.81 ± 166.57 | 509.81 ± 217.80 |
Informational comparison of AUC0-t values for Corrected Unconjugated Estrone.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-t of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) | 10952.25 ± 3887.84 | 11369.60 ± 5058.92 |
Informational comparison of AUC0-inf values for Corrected Unconjugated Estrone.
| pg*h/mL | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| AUC0-inf of Corrected Unconjugated Estrone(Area Under the Concentration-time Curve From Time Zero to Infinity) | 11293.21 ± 3899.12 | 11747.97 ± 5289.05 |
Collected over Adverse event data was collected over the course of the study, which was approximately 6 weeks in duration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Estradiol/Norethindrone Acetate (Test) | — | 0/40 (0%) | 1/40 (2.5%) |
| Activella® (Reference) | — | 0/40 (0%) | 2/40 (5%) |
| Event | Estradiol/Norethindrone Acetate (Test) | Activella® (Reference) |
|---|---|---|
| HeadacheGeneral disorders | 1/40 | 2/40 |
| Age, Categorical(Participants) | Estradiol/Norethindrone Acetate (Test) First | Activella® (Reference) First | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 20 | 20 | 40 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Estradiol/Norethindrone Acetate (Test) First | Activella® (Reference) First | Total |
|---|---|---|---|
| Female | 20 | 20 | 40 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Estradiol/Norethindrone Acetate (Test) First | Activella® (Reference) First | Total |
|---|---|---|---|
| Caucasian | 13 | 15 | 28 |
| Hispanic | 3 | 1 | 4 |
| Black | 2 | 2 | 4 |
| Asian | 2 | 1 | 3 |
| American Indian | 0 | 1 | 1 |
| Region of Enrollment(participants) | Estradiol/Norethindrone Acetate (Test) First | Activella® (Reference) First | Total |
|---|---|---|---|
| Canada | 20 | 20 | 40 |
The record gives a start of Jan 2007, a primary completion of Feb 2007 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2010, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Estradiol · Norethindrone Acetate